OUR MISSION
To conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies

OUR VISION
To be the premier collaborative network for transformative research in gynecologic malignancies
LEARNING OBJECTIVES

Upon completion of the activities in this series, learners will demonstrate:

THE OVERALL OBJECTIVE FOR THIS SESSION IS TO SHOWCASE CLINICAL TRIALS AND OTHER NEWSWORTHY EDUCATION FROM MAJOR MEDICAL MEETINGS THROUGHOUT THE YEAR

Greater competence related to
  • Selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers

Increased knowledge regarding
  • The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
  • The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
  • The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent cervical, endometrial, and ovarian cancers
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*

<table>
<thead>
<tr>
<th>NAME</th>
<th>Individual's Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>DISCLOSURE &lt;company &amp; role&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Herzog, MD</td>
<td>Moderator</td>
<td></td>
<td>Astra Zeneca; Caris; Clovis; Eisai; Epsilogen; Genentech; GSK; J&amp;J; Merck; Mersana; Novocure; Seattle Genetics: Scientific Advisory Boards</td>
</tr>
<tr>
<td>Robert Coleman, MD</td>
<td>Speaker</td>
<td></td>
<td>Agenus; Alkermes, Inc.; AstraZeneca; Clovis Oncology, Inc.; Deciphera Pharmaceuticals Inc.; EisAI INC.; Genentech USA, Inc.; GlaxoSmithKline; Gradalis; Mersana; Novocure Inc.; oncuxena; Regeneron Pharmaceuticals: Consultant AbbVie; Immunogen; Janssen Biotech, Inc.; Merck; Novartis; Onxeo; Seagen Inc.: Grant/Contract; Vbl; Data And Safety Monitoring</td>
</tr>
<tr>
<td>Thomas Herzog, MD</td>
<td>Speaker</td>
<td></td>
<td>Astra Zeneca; Caris; Clovis; Eisai; Epsilogen; Genentech; GSK; J&amp;J; Merck; Mersana; Novocure; Seattle Genetics: Scientific Advisory Boards</td>
</tr>
<tr>
<td>Bhavana Pothuri, MD</td>
<td>Speaker</td>
<td></td>
<td>AstraZeneca; Celision; Immunogen; Merck; Mersana; Seattle Genetics; Sutro; Takada; Tesaro; Clovis Oncology: Research funding support/Ad Board fees: Eisai; Lily; GOG Foundation: Advisory Board</td>
</tr>
<tr>
<td>Leslie Randall, MD</td>
<td>Speaker</td>
<td></td>
<td>AstraZeneca Pharmaceuticals LP; Clovis Oncology, Inc.; GlaxoSmithKline; Immunogen; Seagen Inc.: Consultant</td>
</tr>
<tr>
<td>Ritu Salani, MD, MBA</td>
<td>Speaker</td>
<td></td>
<td>Merck; Eisai; GSK; Seagen; Regeneron; Karyopharm; Immunogen: Ad board/Consultant; Up To Date; Elsevier: Writer</td>
</tr>
<tr>
<td>Angeles Alvarez Secord, MD, MHSc</td>
<td>Speaker</td>
<td></td>
<td>AbbVie; Aravive; AstraZeneca; Clovis Oncology, Inc.; Eisai; Genentech; GSK; Merck; National Cancer Trial Network: Onccoquest; Seagen Inc; Tapimmune; VBL Therapeutics: Grant/Contract; Immunogen; Myriad Genetic Laboratories, Inc.: Consultant; AAOGF; GOG Foundation; SGO: Other</td>
</tr>
<tr>
<td>Brian Slomovitz, MD</td>
<td>Speaker</td>
<td></td>
<td>Abbvie; AstraZeneca; Clovis; GSK; Genentech; Merck; Myriad; Consultant</td>
</tr>
<tr>
<td>Michelle N Small, MPH</td>
<td>Staff</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Jill Reese</td>
<td>Staff</td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>
GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support and sponsorship associated with this Symposium:

AstraZeneca  
GSK  
Seagen, Inc. | Genmab  
ImmunoGen

Genelux  
Acrivon  
R-Pharm
Angeles Alvarez-Secord, MD, MHSc, Duke Cancer Center Institute, Durham, North Carolina, USA
Robert Coleman, MD, Texas Oncology, Vaniam Group, Houston, Texas, USA
Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA
Leslie Randall, MD, MAS Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA
Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA
AGENDA

6:30 pm – 6:35 pm  
**Welcome & Introductions**  
Thomas Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA  
Bradley Monk, MD, Director, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s Hospital and HonorHealth Phoenix, Arizona, USA

6:35 pm – 7:25 pm  
**Cervical Cancer – New Data in CCRT, 1st Line, 2nd Line and How It Impacts Your Clinical Practice**  
Leslie Randall, MD, Massey Comprehensive Cancer Center, Virginia Commonwealth University, USA  
Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA  
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA

7:25 pm – 8:05 pm  
**The Evolution of Ovarian Cancer**  
Angeles Alvarez-Secord, MD, MHSc, Director of Gynecologic Oncology Clinical Trials, Duke Cancer Center Institute, Durham, North Carolina, USA  
Robert Coleman, MD, Texas Oncology, Vanian Group, Houston, Texas, USA

8:05 pm – 8:55 pm  
**Uterine Cancer, The Knowns and Unknowns – A Heated Discussion on Pivotal Changing Data**  
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA  
Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA  
Thomas Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA  
Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA

8:55 pm – 9:00 pm  
**Wrap Up and Announcement of Next GOG Highlight Reel**  
Thomas Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA